GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Cyclically Adjusted Revenue per Share

Theralase Technologies (TSXV:TLT) Cyclically Adjusted Revenue per Share : C$0.00 (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Theralase Technologies's adjusted revenue per share for the three months ended in Mar. 2025 was C$0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is C$0.00 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Theralase Technologies's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -20.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -19.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -15.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Theralase Technologies was -7.20% per year. The lowest was -20.60% per year. And the median was -12.60% per year.

As of today (2025-06-27), Theralase Technologies's current stock price is C$0.185. Theralase Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was C$0.00. Theralase Technologies's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Theralase Technologies was 30.00. The lowest was 4.17. And the median was 10.36.


Theralase Technologies Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Theralase Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Cyclically Adjusted Revenue per Share Chart

Theralase Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.02 0.01 0.01

Theralase Technologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 - 0.01 0.01 -

Competitive Comparison of Theralase Technologies's Cyclically Adjusted Revenue per Share

For the Medical Devices subindustry, Theralase Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theralase Technologies's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Cyclically Adjusted PS Ratio falls into.


;
;

Theralase Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theralase Technologies's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0/129.1809*129.1809
=0.000

Current CPI (Mar. 2025) = 129.1809.

Theralase Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.003 100.500 0.004
201509 0.004 100.421 0.005
201512 0.009 99.947 0.012
201603 0.004 101.054 0.005
201606 0.005 102.002 0.006
201609 0.003 101.765 0.004
201612 0.006 101.449 0.008
201703 0.005 102.634 0.006
201706 0.004 103.029 0.005
201709 0.003 103.345 0.004
201712 0.007 103.345 0.009
201803 0.004 105.004 0.005
201806 0.004 105.557 0.005
201809 0.003 105.636 0.004
201812 0.003 105.399 0.004
201903 0.001 106.979 0.001
201906 0.002 107.690 0.002
201909 0.001 107.611 0.001
201912 0.003 107.769 0.004
202003 0.001 107.927 0.001
202006 0.001 108.401 0.001
202009 0.001 108.164 0.001
202012 0.002 108.559 0.002
202103 0.001 110.298 0.001
202106 0.001 111.720 0.001
202109 0.001 112.905 0.001
202112 0.001 113.774 0.001
202203 0.001 117.646 0.001
202206 0.002 120.806 0.002
202209 0.001 120.648 0.001
202212 0.002 120.964 0.002
202303 0.001 122.702 0.001
202306 0.001 124.203 0.001
202309 0.001 125.230 0.001
202312 0.002 125.072 0.002
202403 0.001 126.258 0.001
202406 0.000 127.522 0.000
202409 0.001 127.285 0.001
202412 0.002 127.364 0.002
202503 0.000 129.181 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Theralase Technologies  (TSXV:TLT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Theralase Technologies was 30.00. The lowest was 4.17. And the median was 10.36.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Theralase Technologies Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 3rd Quarter Trades of Strong Tower Advisory Services

By GuruFocus Research GuruFocus Editor 10-15-2022

Top 5 4th Quarter Trades of Mechanics Bank Trust Department

By GuruFocus Research GuruFocus Editor 01-24-2023

Rafferty Asset Management, LLC's Top 5 Buys of the 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023

Top 5 3rd Quarter Trades of Eqis Capital Management, Inc.

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 3rd Quarter Trades of Barry Investment Advisors, LLC

By GuruFocus Research GuruFocus Editor 10-24-2022

Top 5 2nd Quarter Trades of SYNOVUS FINANCIAL CORP

By GuruFocus Research GuruFocus Editor 08-11-2022

Top 5 3rd Quarter Trades of PINNACLE FINANCIAL PARTNERS INC

By GuruFocus Research GuruFocus Editor 10-31-2022